Skip to main content
. 2020 Sep 13;11(21):6429–6436. doi: 10.7150/jca.47175

Table 4.

Number of site-specific cancer and comparison between different eGFR groups

Site-specific cancer Total number Number of cancer according to eGFR (ml/min/1.73m2) P
eGFR ≥ 90 eGFR 60 to 89 eGFR < 60
brain 5 4 1 0 0.72
Oral cavity 2 1 1 0 1.00
Larynx 7 5 1 1 0.23
Other pharynx 5 3 1 1 0.20
Thyroid 7 6 1 0 0.56
Lung 43 21 15 7 0.001
Breast 12 9 3 0 0.71
Esophagus 24 14 10 0 0.61
Stomach 19 12 6 1 0.66
Liver 33 14 16 3 0.02
Pancreas 7 4 3 0 0.76
Kidney 4 1 1 2 0.007
Prostate 3 2 0 1 0.09
Testicle 0 0 0 0 -
Ovary 4 4 0 0 0.40
Cervix 14 11 3 0 0.63
Endometrium 17 15 2 0 0.13
Colon or rectum 16 5 8 3 0.004
Bladder 4 1 2 1 0.05
Skin 4 1 2 1 0.05
Non-Hodgkin lymphoma 4 3 1 0 1.00
Leukemia 0 0 0 0 -
Other location 35 14 15 6 0.001

Note: Fisher's exact tests were used due to the expected frequency <1.